Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by López-García, F.
Right arrow Articles by Andrade, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by López-García, F.
Right arrow Articles by Andrade, R. J.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 28:752-753, 2005
© 2005 by the American Diabetes Association, Inc.

Letters: Observations

Cholestatic Hepatitis Associated With Repaglinide

Francisco López-García, MD1, Joaquín Borrás, PHARMD, PHD2, Clara Verdú, MD, PHD3, V.R. Salazar, MD4, J. Antonio Ruiz, MD5, Jorge Sales, MD, PHD6, Ma Isabel Lucena, MD, PHD7 and Raúl J. Andrade, MD, PHD8

1 Department of Internal Medicine, Hospital Orihuela, Alicante, Spain
2 Pharmacy Service, Hospital Elche, Alicante, Spain
3 Gastroenterology and Hepatology Service, Hospital Orihuela, Alicante, Spain
4 Department of Internal Medicine, Hospital Orihuela, Alicante, Spain
5 Pathology Service, Hospital Orihuela, Alicante, Spain
6 Endocrinology Service, Hospital Orihuela, Alicante, Spain
7 Clinical Pharmacology Service, Hospital de Málaga, Málaga, Spain
8 Liver Unit, Gastroenterology Service, University Hospital, School of Medicine, Málaga, Spain

Address correspondence to Francisco López-García, MD, Department of Internal Medicine, Hospital Orihuela, Alicante, Maestro Alonso n° 100-1° piso, 03012 Alicante, Spain. E-mail: f.lopezgarcia@terra.es

The first 20% of the full text of this article appears below.

Repaglinide is a fast, short-acting meglitinide analog antidiabetic drug approved for the treatment of type 2 diabetes. Hypoglycemia is a major adverse effect of this drug (1). In rare cases, elevated liver enzymes have been noted (2). We report a patient who developed cholestatic hepatitis while taking repaglinide.

A 72-year-old man had a 2-year history of type 2 diabetes that was initially controlled by diet. He had normal liver function. Two months before presentation, he began taking repaglinide (1 mg/day), and 1 month before presentation, the daily dose was increased to 2 mg. The patient presented because of a . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.